News
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before
EQS-News: Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at 10:15 a.m. ET
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of
Vistagen to Present at Stifel 2024 Virtual CNS Days
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3)
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending
Evolva Holding SA in liquidation: Nice & Green requests 3 agenda items be included in AGM agenda
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at
EQS-News: Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
At a meeting with the investment community today, Pfizer Inc. (NYSE: PFE) outlined its strategic priorities for the newly formed Oncology organization — and how its deep and diverse pipeline
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons
EQS-News: BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives